HORIEN Wins Three Thai FDA Class 4 Approvals for Regenerative Devices and U.S. Patent for Biodegradable Ureteral Stent
核心洞察
HORIEN Biochemical Technology secured Thai FDA Class 4 approvals for three porcine-derived collagen regenerative medical devices, formally opening the Thai market for its biomaterial platform.
The company also received a U.S. invention patent for a biodegradable ureteral stent (搜索) that degrades after healing, eliminating a secondary removal procedure and lowering infection risk.
The three approved devices are a Collagen Bone Graft Matrix for guided bone regeneration, a Collagen Matrix plug and sheet, and an SIS-derived Extracellular Membrane for guided tissue regeneration.
HORIEN Biochemical Technology Co., Ltd. (搜索) (TPEx: 7814) has announced a dual milestone in its global expansion strategy: Thai Food and Drug Administration (搜索) (Thai FDA) Class 4 approvals for three advanced regenerative medical devices, and the grant of a U.S. invention patent covering its biodegradable ureteral stent (搜索). The regulatory clearances establish a formal entry into the Thai market, while the patent extends the company's biomaterial expertise from oral and wound care into urological applications.
Thai FDA Class 4 Portfolio Built on Porcine Collagen
The three newly approved devices form the core of HORIEN's porcine-derived collagen biomaterial portfolio, manufactured using Dehydrothermal Treatment (DHT) and decellularization processes. According to the company, these products provide a versatile framework for clinical deployment across dental, surgical, wound care, and regenerative applications.
The "Horien" Collagen Bone Graft Matrix is a porous, implantable scaffold tailored for Guided Bone Regeneration (GBR) procedures, engineered to provide architecture for natural bone remodeling and cellular integration. The "Horien" Collagen Matrix is a biocompatible collagen plug and sheet designed for rapid fluid absorption, local clot stabilization, and wound coverage across surgical and dental interventions. The third device, the "Horien" Extracellular Membrane, is a resorbable extracellular matrix derived from porcine Small Intestinal Submucosa (搜索) (SIS), specialized for Guided Tissue Regeneration (GTR) and alveolar ridge preservation procedures.
U.S. Patent Targets Urological Pain Points
Parallel to its commercial progress in Southeast Asia, HORIEN has been granted a U.S. invention patent for its biodegradable ureteral stent (搜索). The stent is designed to safely degrade within the body after healing, eliminating the need for a secondary removal procedure and substantially lowering infection risks and patient discomfort. The company describes the patent as significantly expanding its technological moat as it moves into high-value urological applications globally.
"Thailand represents a pivotal cornerstone in HORIEN's Southeast Asian expansion," said Hsin-Yu Ho, General Manager of HORIEN Biochemical Technology Co., Ltd. (搜索) "Securing three Class 4 Thai FDA approvals validates the clinical safety and efficacy of our platform. Paired with our recent U.S. patent breakthrough for biodegradable ureteral stents, we are proving that Taiwanese medical technology stands at the forefront of international innovation."
Market Opportunity Across Three Device Segments
HORIEN frames the Thai market as a substantial commercial opportunity spanning all three focal areas of its biomaterial platform. Citing Grand View Research, the company notes that Thailand's dental equipment and consumables market generated US$383.2 million in 2024 and is projected to reach US$569.5 million by 2030, a CAGR of 6.9%. The general surgery devices market reached US$164.3 million in 2024 and is forecast to hit US$257.6 million by 2030, a CAGR of 7.9%. Thailand's regenerative medicine market stood at US$63.0 million in 2024 and is expected to grow to US$113.9 million by 2030, a CAGR of 10.1%.
The company points to its home-market performance as evidence of commercial maturity. "In Taiwan, our 'Horien' Collagen Matrix alone generates over US$1.2 million in annual revenue, demonstrating strong clinical validation and commercial maturity that we look forward to sharing with our Thai partners," Ho said.
Distribution Strategy and Partner Criteria
With its regulatory foundation established in Thailand, HORIEN is hosting discussions with potential partners for exclusive or strategic regional distribution rights. The company states that preference will be given to distributors with established networks in dental, surgical, and regenerative medicine channels, robust regulatory compliance capabilities, and dedicated resources for clinician training and local market engagement.
HORIEN lists several benefits for prospective Thai partners: immediate market access with a Thai FDA-approved Class 4 product portfolio; scalable, ISO/GMP-certified manufacturing capabilities; product training, scientific support, and technical education for local teams; co-marketing resources and business development assistance; and long-term collaboration with a publicly listed biomaterials developer. The company's stated priority in Thailand is to establish sustainable partnerships with distributors that have deep clinical reach and a commitment to professional medical education.
Company Profile
HORIEN Biochemical Technology Co., Ltd. (搜索) is a Taiwan-based biomedical company specializing in the research, development, and commercialization of regenerative biomaterials for dental, oral surgery, wound care, tissue regeneration, and urological applications. The company reports maintaining a dominant position in Taiwan's dental biomaterials market while expanding globally through FDA regulatory approvals, strategic patents, and international distribution partnerships.